ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study
ImmunityBio’s immunotherapy combination regimen has demonstrated its early potential during a mid-stage trial in patients with glioblastoma and severe lymphopenia.…
Oncology
-
-
Corcept’s stock up as relacorilant meets OS goal in Phase III ovarian cancer trial
Corcept Therapeutics’ stock has risen 14% after its selective cortisol modulator relacorilant met its overall survival (OS) goal in a…
-
ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months
ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK) showed over 15…
-
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
ImmunityBio’s immunotherapy drug Anktiva (nogapendekin alfa inbakicept) has shown success in combination with a checkpoint inhibitor in two non-small cell…
-
JPM26: Roche’s rejuvenation strategy for the oncology and haematology portfolio
At the J.P. Morgan Healthcare Conference 2026, Roche Pharma’s CEO, Teresa Graham, shared the company’s vision for the next few…
-
Genmab shelves Phase III lung cancer candidate
Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including…
-
Immuneering progresses MAPK inhibitor in lung and pancreatic cancer
Immuneering is set to progress its lead oncology candidate, atebimetinib, to the next stage of clinical development in both first-line…
-
AstraZeneca’s NSCLC combo fails to meet primary endpoint in Phase III trial
AstraZeneca’s combination therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) has failed to meet the primary endpoint…
-
Precision medicine approaches needed in oncology to match evolving SoC
As the standard of care (SoC) for new drugs in oncology continues to improve, trials need to be designed with…
-
ASH 2025: J&J’s Tecvayli + Darzalex set to redefine early relapsed MM
At the American Society of Hematology (ASH) Annual Meeting 2025, held in Orlando, Florida, from 6 to 9 December, updated…
